Drug Profile
MB 101
Alternative Names: MB-101Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Miltenyi Biotec GmbH
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Unspecified in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Germany
- 25 Jun 2013 Preclinical trials in Undefined indication in Germany (unspecified route)